vs
Ingevity Corp（NGVT）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Ingevity Corp的季度营收约是VERACYTE, INC.的1.3倍（$185.4M vs $140.6M），VERACYTE, INC.净利率更高（29.3% vs -45.6%，领先74.9%），Ingevity Corp同比增速更快（36.7% vs 18.5%），Ingevity Corp自由现金流更多（$73.5M vs $48.8M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -26.2%）
Ingevity Corp是一家全球特种化学品与先进材料生产商，主营高性能碳材料、路面养护解决方案及特种化工产品，服务汽车排放控制、工业净化、道路基建、农业投入品等核心市场，业务覆盖北美、欧洲及亚太地区。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
NGVT vs VCYT — 直观对比
营收规模更大
NGVT
是对方的1.3倍
$140.6M
营收增速更快
NGVT
高出18.2%
18.5%
净利率更高
VCYT
高出74.9%
-45.6%
自由现金流更多
NGVT
多$24.7M
$48.8M
两年增速更快
VCYT
近两年复合增速
-26.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.4M | $140.6M |
| 净利润 | $-84.6M | $41.1M |
| 毛利率 | 41.2% | 72.5% |
| 营业利润率 | -47.7% | 26.4% |
| 净利率 | -45.6% | 29.3% |
| 营收同比 | 36.7% | 18.5% |
| 净利润同比 | -609.6% | 704.8% |
| 每股收益（稀释后） | $-2.33 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NGVTVCYT
| Q4 25 | $185.4M | $140.6M | ||
| Q3 25 | $333.1M | $131.9M | ||
| Q2 25 | $365.1M | $130.2M | ||
| Q1 25 | $284.0M | $114.5M | ||
| Q4 24 | $135.6M | $118.6M | ||
| Q3 24 | $333.8M | $115.9M | ||
| Q2 24 | $390.6M | $114.4M | ||
| Q1 24 | $340.1M | $96.8M |
净利润NGVTVCYT
| Q4 25 | $-84.6M | $41.1M | ||
| Q3 25 | $43.5M | $19.1M | ||
| Q2 25 | $-146.5M | $-980.0K | ||
| Q1 25 | $20.5M | $7.0M | ||
| Q4 24 | $16.6M | $5.1M | ||
| Q3 24 | $-107.2M | $15.2M | ||
| Q2 24 | $-283.7M | $5.7M | ||
| Q1 24 | $-56.0M | $-1.9M |
毛利率NGVTVCYT
| Q4 25 | 41.2% | 72.5% | ||
| Q3 25 | 40.2% | 69.2% | ||
| Q2 25 | 37.8% | 69.0% | ||
| Q1 25 | 39.9% | 69.5% | ||
| Q4 24 | 81.3% | 66.4% | ||
| Q3 24 | 39.4% | 68.2% | ||
| Q2 24 | 31.5% | 68.1% | ||
| Q1 24 | 29.3% | 64.5% |
营业利润率NGVTVCYT
| Q4 25 | -47.7% | 26.4% | ||
| Q3 25 | 18.7% | 17.4% | ||
| Q2 25 | -39.1% | -4.0% | ||
| Q1 25 | 9.4% | 2.5% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | 33.0% | 10.4% | ||
| Q2 24 | 25.9% | 4.0% | ||
| Q1 24 | 22.6% | -4.8% |
净利率NGVTVCYT
| Q4 25 | -45.6% | 29.3% | ||
| Q3 25 | 13.1% | 14.5% | ||
| Q2 25 | -40.1% | -0.8% | ||
| Q1 25 | 7.2% | 6.2% | ||
| Q4 24 | 12.2% | 4.3% | ||
| Q3 24 | -32.1% | 13.1% | ||
| Q2 24 | -72.6% | 5.0% | ||
| Q1 24 | -16.5% | -1.9% |
每股收益（稀释后）NGVTVCYT
| Q4 25 | $-2.33 | $0.50 | ||
| Q3 25 | $1.18 | $0.24 | ||
| Q2 25 | $-4.02 | $-0.01 | ||
| Q1 25 | $0.56 | $0.09 | ||
| Q4 24 | $0.44 | $0.07 | ||
| Q3 24 | $-2.94 | $0.19 | ||
| Q2 24 | $-7.81 | $0.07 | ||
| Q1 24 | $-1.54 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.1M | $362.6M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $29.7M | $1.3B |
| 总资产 | $1.7B | $1.4B |
| 负债/权益比越低杠杆越低 | 39.10× | — |
8季度趋势，按日历期对齐
现金及短期投资NGVTVCYT
| Q4 25 | $78.1M | $362.6M | ||
| Q3 25 | $83.4M | $315.6M | ||
| Q2 25 | $76.9M | $219.5M | ||
| Q1 25 | $71.5M | $186.1M | ||
| Q4 24 | $68.0M | $239.1M | ||
| Q3 24 | $135.5M | $274.1M | ||
| Q2 24 | $107.4M | $235.9M | ||
| Q1 24 | $88.5M | $209.2M |
总债务NGVTVCYT
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益NGVTVCYT
| Q4 25 | $29.7M | $1.3B | ||
| Q3 25 | $138.1M | $1.3B | ||
| Q2 25 | $120.7M | $1.2B | ||
| Q1 25 | $234.6M | $1.2B | ||
| Q4 24 | $195.2M | $1.2B | ||
| Q3 24 | $214.5M | $1.2B | ||
| Q2 24 | $284.8M | $1.1B | ||
| Q1 24 | $568.2M | $1.1B |
总资产NGVTVCYT
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.8B | $1.4B | ||
| Q2 25 | $1.9B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.0B | $1.3B | ||
| Q3 24 | $2.2B | $1.3B | ||
| Q2 24 | $2.3B | $1.2B | ||
| Q1 24 | $2.6B | $1.2B |
负债/权益比NGVTVCYT
| Q4 25 | 39.10× | — | ||
| Q3 25 | 8.39× | — | ||
| Q2 25 | 10.24× | — | ||
| Q1 25 | 5.68× | — | ||
| Q4 24 | 6.86× | — | ||
| Q3 24 | 6.52× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 2.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.1M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $73.5M | $48.8M |
| 自由现金流率自由现金流/营收 | 39.6% | 34.7% |
| 资本支出强度资本支出/营收 | 12.7% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $273.5M | $126.6M |
8季度趋势，按日历期对齐
经营现金流NGVTVCYT
| Q4 25 | $97.1M | $52.6M | ||
| Q3 25 | $129.7M | $44.8M | ||
| Q2 25 | $79.0M | $33.6M | ||
| Q1 25 | $25.4M | $5.4M | ||
| Q4 24 | $64.5M | $24.5M | ||
| Q3 24 | $46.5M | $30.0M | ||
| Q2 24 | $29.7M | $29.6M | ||
| Q1 24 | $-12.1M | $-9.0M |
自由现金流NGVTVCYT
| Q4 25 | $73.5M | $48.8M | ||
| Q3 25 | $117.8M | $42.0M | ||
| Q2 25 | $66.8M | $32.3M | ||
| Q1 25 | $15.4M | $3.5M | ||
| Q4 24 | $39.6M | $20.4M | ||
| Q3 24 | $28.5M | $27.7M | ||
| Q2 24 | $11.6M | $26.8M | ||
| Q1 24 | $-28.7M | $-11.1M |
自由现金流率NGVTVCYT
| Q4 25 | 39.6% | 34.7% | ||
| Q3 25 | 35.4% | 31.8% | ||
| Q2 25 | 18.3% | 24.8% | ||
| Q1 25 | 5.4% | 3.1% | ||
| Q4 24 | 29.2% | 17.2% | ||
| Q3 24 | 8.5% | 23.9% | ||
| Q2 24 | 3.0% | 23.4% | ||
| Q1 24 | -8.4% | -11.5% |
资本支出强度NGVTVCYT
| Q4 25 | 12.7% | 2.7% | ||
| Q3 25 | 3.6% | 2.1% | ||
| Q2 25 | 3.3% | 1.0% | ||
| Q1 25 | 3.5% | 1.6% | ||
| Q4 24 | 18.4% | 3.5% | ||
| Q3 24 | 5.4% | 1.9% | ||
| Q2 24 | 4.6% | 2.4% | ||
| Q1 24 | 4.9% | 2.2% |
现金转化率NGVTVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | 2.98× | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.24× | 0.76× | ||
| Q4 24 | 3.89× | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
